Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Inclusion Criteria

• Confirmed HIV-1 infection, defined as positive results from two samples collected at different time points (see protocol for more information)
• Participant belonged to one of the ARV exposure groups below:
• ARV-treatment experienced (not including receipt of ARVs as prophylaxis or for prevention of perinatal transmission)
• Previously took ARVs for treatment, but not taking ARVs at study screening.
• Had been off treatment for greater than or equal to 4 weeks prior to screening, OR
• At screening, taking ARVs for treatment but failing.
• Was on an unchanged, failing therapeutic regimen within the 4 to 12 weeks prior to screening (less than or equal to 1 log drop in HIV-1 RNA within the 4 to 12 weeks prior to screening). OR
• For participants less than 2 years of age, initiated ARVs for treatment less than 4 weeks prior to screening.
• ARV treatment naive (no exposure to ARVs for treatment; could have received ARVs for prophylaxis or prevention of perinatal transmission)
• If an infant had received nevirapine (NVP) as prophylaxis to prevent perinatal transmission, he or she did not receive NVP for at least 14 days prior to enrollment into Stage I or II.
• HIV-1 RNA viral load greater than 1,000 copies/mL of plasma at screening.
• Demonstrated ability or willingness to swallow assigned study medications.
• Parent or legal guardian were able and willing to provide signed informed consent.
• Female participants of reproductive potential, defined as having reached menarche, and who were engaging in sexual activity that could lead to pregnancy, agreed to use two contraceptive methods while on study and for two weeks after stopping study drug.
• Males engaging in sexual activity that could lead to HIV-1 transmission agreed to use a condom.
• Agreed to stay on optimized background therapy (OBT) while on study:
• Participants who at screening were greater than or equal to 2 years of age and ARV-treatment experienced, had at screening at least one fully active drug for the OBT.
• Participants who were greater than or equal to 2 years of age and ARV-treatment naïve, had genotype testing at screening/entry even with results pending.
• Participants less than 2 years of age (either ARV-treatment experienced or ARV treatment naïve), had genotype testing at screening/entry even with results pending.

Exclusion Criteria

• Presence of any active AIDS-defining opportunistic infection
• At enrollment, participant less than 3.0 kg
• Known Grade 3 or greater of any of the following laboratory toxicities within 30 days prior to study entry: neutrophil count, hemoglobin, platelets, aspartate aminotransferase (AST), alanine transaminase (ALT), lipase, serum creatinine and total bilirubin. A single repeat within the 30 days is allowed for eligibility determination. NOTE: Grade 3 total bilirubin was allowable, if the participant was on atazanavir (ATV).
• ANY known Grade 4 laboratory toxicities within 30 days prior to study entry. NOTE: Grade 4 total bilirubin was allowable, if the participant was on ATV.
• The following liver toxicities within 30 days prior to study entry: ALT greater than 3x the upper limit of normal (ULN) AND direct bilirubin was greater than 2x ULN
• Any prior history of malignancy, with the exception of localized malignancies such as squamous cell or basal cell carcinoma of the skin
• Clinical or symptomatic evidence of pancreatitis, as determined by the clinician
• Use of any disallowed medications at time of screening (see the protocol for a complete list of disallowed medications)
• Known history of exposure to integrase inhibitor treatment by the participant or participant's mother prior to delivery/cessation of breastfeeding
• Known resistance to an integrase inhibitor
• Women who were pregnant or breastfeeding
• At screening/entry, participating in or had participated in a study with a compound or device that was not commercially available within 30 days of signing informed consent, unless perm